| Name | Title | Contact Details |
|---|
Restore Hyper Wellness is the award-winning creator of an innovative new category of care—Hyper Wellness®. Restore delivers expert guidance and an extensive array of cutting-edge health modalities, such as IV drips and cryotherapy, integrated under one roof. These modalities help you feel your best, so you can do more of what you love. With 120+ locations across 34+ states and a fast-growing national retail footprint, Restore makes proactive health more accessible than ever.
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.
Ratio Corp is a Pompano Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
lcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx`s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets.
First DataBank, Inc. is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.